New cancer pill enters first human tests

NCT ID NCT06724042

Not yet recruiting Disease control Sponsor: InSilico Medicine Hong Kong Limited Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This early-phase trial tests an experimental drug called ISM5939, taken as a pill, in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study will first test the drug alone, then in combination with chemotherapy (cisplatin or docetaxel) or immunotherapy (pembrolizumab). The main goals are to check safety, find the right dose, and see if the drug shows any signs of shrinking tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ISM5939 (an experimental oral drug, tested alone and with cisplatin, docetaxel, or pembrolizumab)
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong: This is a very early (Phase 1) trial, so the drug may not be safe or effective. Side effects are unknown, and the study is small, so results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED AND/OR METASTATIC SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED AND/OR METASTATIC SOLID TUMORS ADVANCED SOLID TUMOR METASTATIC SOLID TUMOR

More trials for these conditions

Other studies related to the condition(s) this trial covers.